Latest
News & Articles

TMCx Demo Day - CNSDose

Texas Medical Center, June, 2017

To celebrate the culmination of the four-month TMCx accelerator program, 22 digital health startups showcased the progress they have made, and what they have planned for the future.

CNSDose offers a genomic solution to fast-track finding the right antidepressant.

For original video, see TMCx Demo Day - CNSDose

Reference: Texas Medical Center (June, 2017) TMCx Demo Day - CNSDose

Tech in Mental Health - CNSDose

Tech in Mental Health, June, 2017

Tech in Mental Health is a podcast about emerging technology in the mental health space.

In episode 8, David Mou and David Ricupero are joined by Harris Eyre. Harris is the Chief Medical Officer at CNSDose. CNSDose uses advanced gene testing to help patients find the right antidepressant faster.

For original audio, click Tech in Mental Health - CNSDose

Reference: David Ricupero, Tech in Mental Health (June, 2017) Ep 8 - Harris Eyre of CNSDose

Texas Medical Center takes on Australian health innovators

Labonline, June, 2017

Three Australian start-up companies have just returned from a four-month stay at the Texas Medical Center (TMC) — the largest medical centre in the world. With an extensive campus of 21 hospitals, 50 non-profit organisations and eight academic and research institutions, TMC concentrates its operations and research on genomics, regenerative medicine, innovation, clinical trials and health policies.

TMC also runs the TMCx accelerator program, which provides start-ups with shared workspace, a curriculum tailored to the needs of healthcare entrepreneurs and the guidance of over 120 industry advisers. Companies also have access to the medical centre itself, all without membership fees or equity sharing.

CNSDose, WardMM and Personify Care participated in the first Australian intake into TMCx, from February–May 2017, as part of the Bio-Bridge initiative — a partnership between TMC and Australia’s medical technology sector. Facilitated by Austrade, Bio-Bridge aims to provide the foundations for a long-term bilateral innovation and technology transfer between Australia and the US.

For full article, see Texas Medical Center takes on Australian health innovators

Reference: LabOnline Staff, Labonline (June, 2017) Texas Medical Center takes on Australian health innovators

CNSDose to Demonstrate Leading Genetic Technology for Prescribing Antidepressants at the American Psychiatric Association Annual Meeting

Benzinga, May, 2017

CNSDose is a genetically drive, clinically proven, decision support tool that helps avoid the lengthy trial and error process by finding the right antidepressant faster. CNSDose speeds recovery and reduces side effects for patients. It can also strengthen the doctor-patient relationship through a personalized approach to treatment.

A peer-reviewed and published, 12-week double-blind randomized controlled trial (RCT) that compared genetically guided and unguided antidepressant prescribing demonstrated positive results. The trial showed 72% of patients experienced full symptom recovery when using CNSDose compared to 28% of patients using trial and error. A recent review undertaken by the Department of Veterans Affairs Health Administration noted that, "CNSDose has the most favorable preliminary findings." The CNSDose RCT was followed by another independent study, also peer-reviewed, that supported the RCT and showed > 85% accuracy, sensitivity, and specificity.

For full article, see CNSDose to Demonstrate Leading Genetic Technology for Prescribing Antidepressants at the American Psychiatric Association Annual Meeting

Reference: Graham Anderson, PRWEB (May, 2017) CNSDose to Demonstrate Leading Genetic Technology for Prescribing Antidepressants at the American Psychiatric Association Annual Meeting

Evidence Brief: Pharmacogenomics-guided Antidepressant Treatment versus Usual Care for Major Depressive Disorder

U.S. Department of Veterans Affairs, July, 2016

Genetic variation has long been explored as a potential contributor to individual differences in antidepressant treatment outcome. Whether using genetic information can help predict how an individual might respond to a particular antidepressant – referred to as 'pharmacogenomics' – is of great interest for further advancing precision medicine efforts. The clinical rationale behind using pharmacogenomic data to inform antidepressant therapy is that a patient's unique genetic profile may help predict whether a patient will tolerate or respond to a drug, or help tailor the dose that will have the best effectiveness and tolerability.

In January 2015, the White House identified VA as a participating agency in the Precision Medicine Initiative, which takes into account individual differences in people's genes, environments, and lifestyles. To inform this initiative, VA's Office of Research and Development (ORD) is developing a clinical study that builds on the Million Veteran Program (MVP) by implementing Precision Medicine in Mental Health (PMH). The PMH committee focused on depression because of its high prevalence, a need for better treatment strategies, and a growing use of genetic testing for decision-making. To inform study development, ORD commissioned the Evidence-based Synthesis Program Coordinating Center (ESP CC) to conduct an evidence brief on the clinical utility of pharmacogenomics-guided treatment for major depressive disorder (MDD).

For full article, see Evidence Brief: Pharmacogenomics-guided Antidepressant Treatment versus Usual Care for Major Depressive Disorder

Reference: U.S. Department of Veterans Affairs (July, 2016) Evidence Brief: Pharmacogenomics-guided Antidepressant Treatment versus Usual Care for Major Depressive Disorder

Melbourne startup CNSDose secures $1 million and brings former trade minister Andrew Robb on as an advisor

Startup Smart, Denham Sadler, July 13th, 2016

A Melbourne biotech startup has secured nearly $1 million in seed funding and brought former federal trade minister Andrew Robb on as an advisor as it looks to improve the way antidepressants are prescribed.

CNSDose is working to develop a genomic test to tailor the prescription of antidepressants for patients and avoid the need for trial and error when prescribing.

The concept has been developed by registered psychiatrist and CNSDose founder Ajeet Singh across nearly a decade.

A DOSE OF SEED FUNDING

The startup recently closed a seed round of nearly $1 million from two anonymous individuals, with the funding used for a trial launch in the US in October.

For full article, see Melbourne startup CNSDose secures $1 million and brings former trade minister Andrew Robb on as an advisor

Reference: Denham Sadler (July 13th, 2016) Melbourne startup CNSDose secures $1 million and brings former trade minister Andrew Robb on as an advisor

Schedule a demo